Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Tocris Bioscience™ A 1331852

Click to view available options
Quantity:
10 mg
Description
A 1331852 is a high affinity and selective Bcl-xL inhibitor (Ki <0.01 nM), also inhibits Bcl-W, Bcl-2, and Mcl-1 (Ki values are 4, 6 and 142 nM, respectively). A 1331852 inhibits Bcl-xL-dependent Molt 4 acute lymphoblastic leukemia cell growth in vitro (EC50 = 6 nM). It enhances antitumor effects of Docetaxel (Cat. No. 4056) and Venetoclax (Cat. No. 6960) in xenograft models of breast and lung cancer. A 1331852 also induces apoptosis in and clears senescent biliary epithelial cells (BECs), and induces apoptosis in xenograft models of EBV-associated T- and natural killer cell lymphoma.
Specifications
Specifications
Chemical Name or Material | 6-[8-[(2-Benzothiazolylamino)carbonyl]-3,4-dihydro-2(1 H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7 ]dec-1-ylmethyl)-1 H-pyrazol-4-yl]-2-pyridinecarboxylic acid |
CAS | 1430844-80-6 |
Quantity | 10 mg |
Target | Bcl-xL |
Molecular Formula | C38H38N6O3S |
Purity | 0.98 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction